Selling a trait: royalty structures in crop science

Agri-science businesses of the size the firm advises rarely sell a company. They sell the right to use a trait in a territory, in a crop, for a period, and they keep everything else. That is a licensing transaction dressed as a corporate one, and the value sits almost entirely in clauses a generalist adviser treats as boilerplate. Where the royalty is calculated, what it is calculated on and who audits the calculation decide the outcome for the developer.

Royalties are struck at one of three points in the chain. A rate on seed sold is simple to audit and easy to erode, because the licensee controls the price of the seed. A rate on area planted is harder to verify and immune to seed pricing. A share of value created, measured against a control variety, aligns the parties and generates a decade of argument about the control. Our advice depends on how much visibility the developer will retain after completion, which is usually very little.

Stacking is the structural risk. A commercial variety may carry four or five traits from different owners, and each owner wants a royalty. Where the licence is silent on how the total is apportioned, the last trait added absorbs the squeeze, and the developer who negotiated first in time is frequently paid last in practice. We insist on an apportionment mechanism and a floor per unit, and we price a licence without one at a substantial discount to a licence with one.

Regulatory approval sits with the licensee while the risk sits with the developer. A trait is approved for cultivation and for import market by market, and a licensee that does not pursue an approval simply does not pay a royalty in that territory. Diligence obligations therefore need to be specific: named markets, dated milestones and a reversion of rights if a milestone is missed. Vague endeavours language is the most common defect our desk finds in licences signed without an adviser.

Bargaining power in this sector is unusually asymmetric. Trait development is fragmented across research institutes, small science companies and family-held breeders, while commercialisation is concentrated in a handful of seed distributors per region. A developer negotiating alone faces a counterparty that signs twenty such agreements a year and has read every clause before. Advisory value is therefore not introduction, since the parties already know each other. It is the drafting of the economics.

Brazil and South Africa are where the firm's agri-science coverage is concentrated, because both combine a large planted area with a domestic breeding community selling into international distribution. Mandates in the two markets share a shape: a developer with a proven trait, a distributor with reach, and fifteen years of payments to be settled in six weeks. The advantage is structural, the conversion is contractual, and the proceeds fund positions with nothing to do with agriculture.

Published 2021-07-21 by the Investment Banking division. Research is prepared for eligible counterparties and does not constitute advice.